1 completed, 1 no longer available, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Endevica Bio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy TCMCB07, Placebo - Cancer Weight Loss | Phase 2 | Recruiting | Endevica Bio | 120 | 2025-04-28 | 2026-07-15 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects TCMCB07, Placebo - Cachexia | Phase 1 | Completed | Endevica Bio | 76 | 2022-07-12 | 2024-02-21 |
| Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC mifomelatide - Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma | No longer available | Endevica Bio | 2026-02-18 |
Cachexia (2) · Pancreatic Neoplasms (2) · Anophthalmia with pulmonary hypoplasia (1) · Colorectal Neoplasms (1) · Weight Loss (1)
United States (2) · Canada (1)
Maria Bermudez, MD, CPI (1) · Meghan Joly, PhD (1)